Skip to main content
. 2022 Oct 14;9:926979. doi: 10.3389/fcvm.2022.926979

FIGURE 4.

FIGURE 4

Comparison of SGLT2 inhibitor vs. control group on the risks of (A) MACE; (B) CV death; (C) HHF. SGLT2, Sodium-glucose cotransporter 2; MACEs, major adverse cardiac events; CV death, cardiovascular death; HHF, hospitalization for heart failure.